These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35903943)

  • 1. Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma.
    Orachum P; Temtanakitpaisan A; Kleebkaow P; Chumworathayi B; Luanratanakorn S; Aue-Angkul A; Itarat Y
    Obstet Gynecol Sci; 2022 Sep; 65(5):459-467. PubMed ID: 35903943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers.
    Biatta CM; Paudice M; Greppi M; Parrella V; Parodi A; De Luca G; Cerruti GM; Mammoliti S; Caroti C; Menichini P; Fronza G; Pesce S; Marcenaro E; Vellone VG
    Front Immunol; 2023; 14():1221605. PubMed ID: 37680633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized p53 immunohistochemistry is an accurate predictor of
    Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
    J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
    Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
    J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 7. Ovarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes.
    Dhillon G; Llaurado-Fernandez M; Tessier-Cloutier B; Sy K; Bassiouny D; Han G; Wong NKY; McRae K; Kinloch M; Pors J; Hopkins L; Covens A; Köbel M; Lee CH; Carey MS
    Front Oncol; 2024; 14():1408196. PubMed ID: 39220645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
    Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
    Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC).
    Oturkar CC; Gandhi N; Rao P; Eng KH; Miller A; Singh PK; Zsiros E; Odunsi KO; Das GM
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omental Macrophagic "Crown-like Structures" Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer.
    Liang YL; Lin CN; Tsai HF; Wu PY; Lin SH; Hong TM; Hsu KF
    Curr Oncol; 2021 Oct; 28(5):4234-4246. PubMed ID: 34677277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiophrenic Lymph Node Metastasis of Ovarian High-grade Serous Carcinoma Showing Wild-type p53 Immunostaining Pattern and Aberrant CD56 Expression.
    Kwon HJ; Oh M; Han J; Song SY; Kim HS
    Int J Surg Pathol; 2021 Dec; 29(8):864-869. PubMed ID: 33764173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer.
    Park E; Han H; Choi SE; Park H; Woo HY; Jang M; Shim HS; Hwang S; Kang H; Cho NH
    Diagnostics (Basel); 2022 Feb; 12(3):. PubMed ID: 35328131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis.
    Sallum LF; Andrade L; Ramalho S; Ferracini AC; de Andrade Natal R; Brito ABC; Sarian LO; Derchain S
    Oncotarget; 2018 Mar; 9(22):15818-15827. PubMed ID: 29662608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
    Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
    Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
    Qu H; Xia Y; Li X
    Curr Gene Ther; 2020; 20(4):313-320. PubMed ID: 32851960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.